(Q38826176)

6 September 2017

1 reference

title

Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights (English)

1 reference

6 September 2017

1 reference

Matthias Götte

1

1 reference

PubMed ID

27147491

6 September 2017

Jordan J Feld

series ordinal

2

1 reference

PubMed ID

27147491

6 September 2017

language of work or name

English

0 references

publication date

5 May 2016

1 reference

Nature Reviews Gastroenterology & Hepatology

6 September 2017

1 reference

6 September 2017

13

1 reference

6 September 2017

6

1 reference

6 September 2017

338-351

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2016.60

6 September 2017

0 references

cites work

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

The changing epidemiology and natural history of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Targets for antiviral therapy of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Emerging therapies for the treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Robust hepatitis C virus infection in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Complete replication of hepatitis C virus in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

A macrocyclic HCV NS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Molecular Mechanisms of Viral and Host Cell Substrate Recognition by Hepatitis C Virus NS3/4A Protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Mechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

General Catalytic Deficiency of Hepatitis C Virus RNA Polymerase with an S282T Mutation and Mutually Exclusive Resistance towards 2'-Modified Nucleotide Analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Hepatitis C virus NS5A: enigmatic but still promiscuous 10 years on!

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

The domain 2 of the HCV NS5A protein is intrinsically unstructured

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Interferon-free strategies with a nucleoside/nucleotide analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

A Refined Model of the HCV NS5A protein bound to daclatasvir explains drug-resistant mutations and activity against divergent genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Preliminary study of two antiviral agents for hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

A genome-wide genetic screen for host factors required for hepatitis C virus propagation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Host-targeting agents in the treatment of hepatitis C: a beginning and an end?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Hepatitis C virus therapeutic development: in pursuit of "perfectovir".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Structural analysis of asunaprevir resistance in HCV NS3/4A protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.60

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Dac

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27147491

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRGASTRO.2016.60

1 reference

6 September 2017

1 reference

PubMed ID

27147491